We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

2

Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.

Thorpe KE, Joski P, Johnston KJ.

Kenneth Thorpe, from Emery University in Atlanta, and his colleagues found in a study carried out in the USA, that while the overall number of bacterial infections remained relatively constant between 2002 and 2014, rising from 13.5 million to 14.3 million annually, the proportion that were antibiotic-resistant rose dramatically, from 5.2% to 11.0%. Patients with antibiotic-resistant infections had spending for bacterial infection that was 165 percent higher than spending by patients without such infections. Sixty-one percent of antibiotic-resistant infections were associated with urinary tract infections. Their conclusion is that the direct costs and the mortality and morbidity attributable to antibiotic-resistant infections make a compelling case for urgent action by national and international policy makers.

Read more

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is proud to announce new agreements for the distribution of its medical device GELSECTAN® with Klinge (Germany), Tramedico (Benelux), Montavit (Austria), Galenica (Greece, Romania Bulgaria and Cyprus), Lapidot (Israel) and Sabora (Finland). These partnerships come after the successful partnership with Norgine in Spain and Portugal, where GELSECTAN® is already on the market. Irritable bowel syndrome is a burdensome disease which has an estimated global prevalence of more than 10%, predominantly affecting adults, especially women, of working age.

Read more

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.

Read more

Let's meet in..

2018, Oct 09

CPhI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more